Figure 1From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular eventsTime to first event (occurrence of any component of the 4P-MACE composite of CV death, MI, stroke, or UAP with hospitalization) for patients receiving linagliptin versus total comparators. CV, cardiovascular; MI, myocardial infarction; UAP, unstable angina pectoris.Back to article page